Hydramicromelin B is primarily investigated for its potential antitumor and anticancer properties. It has shown inhibitory effects on specific cancer cell lines by interfering with cell proliferation and inducing apoptosis. Its mechanism involves targeting key signaling pathways involved in tumor growth and survival. Due to its bioactive nature, it is used in preclinical research to develop novel chemotherapeutic agents. Additionally, it serves as a lead compound in structure-activity relationship studies aimed at optimizing efficacy and reducing toxicity in cancer treatment. Research is ongoing to evaluate its potential in combination therapies and targeted drug delivery systems.